TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10833065

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) supplementation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: N-3 fatty acids plus antioxidants (AO) supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9221486

Group type: EXPERIMENTAL
Intervention: 0.5 mg human calcitonin (hCT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1441864

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg rectally 12 h and 1 h before surgery and 20 mg 24 h postoperatively
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Piroxicam and Placebo)
Number of subjects: 28
Study: 3516580

Group type: EXPERIMENTAL
Intervention: 100 mg fenoverine 3-times daily for 20 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 150 mg trimebutine 3-times daily for 20 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: fenoverine
Number of subjects: 40

Group type: COMPARATOR
Intervention: trimebutine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: fenoverine and trimebutine
Number of subjects: 40
Study: 30570679

Group type: EXPERIMENTAL
Intervention: 2.5 mg albuterol delivered via a jet nebulizer with a facial mask
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2.5 mg albuterol delivered via a vibrating mesh nebulizer placed downstream of a nasal high-flow humidification chamber (30 L/min and 37 °C)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nasal high-flow therapy without nebulization
Number of subjects: 25
Study: 27031649

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST) with laparoscopic cholecystectomy (LC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Laparoscopic common bile duct exploration during LC
Number of subjects: 51
Study: 24472002

Group type: EXPERIMENTAL
Intervention: 1-week stenting (1W series)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4-week stenting (4W series)
Number of subjects: 100
Study: 22882579

Group type: EXPERIMENTAL
Intervention: Simple mixed-dilution OL-HDF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simple mid-dilution OL-HDF
Number of subjects: 12
Study: 21054971

Group type: EXPERIMENTAL
Intervention: Tecnis multifocal aspheric IOL (Tecnis ZM900, AMO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monofocal spherical IOL (Akreos Adapt, Bausch & Lomb)
Number of subjects: 100
Study: 18936645

Group type: EXPERIMENTAL
Intervention: BMI < 30 kg/m2
Number of subjects: 964

Group type: COMPARATOR
Intervention: BMI >= 30 kg/m2
Number of subjects: 964
Study: 15805196

Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip arthroplasty (short incision <or=10 cm)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard incision total hip arthroplasty (16 cm)
Number of subjects: 219
Study: 12879670

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg.kg-1 bolus followed by a continuous infusion of 12 mg.kg-1.h-1)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 93
Study: 11008847

Group type: EXPERIMENTAL
Intervention: Decision-making training addressing both cognitive and motivational aspects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Decision-making training including only cognitive aspects
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 8838779

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex) at a starting dose of 40 mg/day, increased by 40 mg/day every 6 weeks until target dose achieved.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 1383958

Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing (DDD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rate modulated ventricular pacing (VVI,R)
Number of subjects: 17
Study: 2998802

Group type: EXPERIMENTAL
Intervention: co-dergocrine (Hydergine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30863852

Group type: EXPERIMENTAL
Intervention: 1 week of AmB and 5FC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 weeks of oral FLU and 5FC
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 weeks of AmB and 5FC
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 weeks of AmB and FLU
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 week of AmB and FLU
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 weeks of oral 5FC and FLU
Number of subjects: 0
Study: 28992261

Group type: EXPERIMENTAL
Intervention: 2 doses of measles vaccine (MV) at 4.5 and 9 months of age
Number of subjects: 5626

Group type: COMPARATOR
Intervention: 1 dose of measles vaccine (MV) at 9 months of age
Number of subjects: 5626
Study: 26576710

Group type: EXPERIMENTAL
Intervention: Tanezumab (200 μg/kg intravenous, 20 mg intravenous, 20 mg subcutaneous)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 25318924

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 696

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 696
Study: 23019947

Group type: EXPERIMENTAL
Intervention: Fibrinogenase for injection + Sanmiao Powder (SP) administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fibrinogenase for injection alone
Number of subjects: 80
Study: 20573755

Group type: EXPERIMENTAL
Intervention: Exercise- or diet-induced weight loss intervention
Number of subjects: 106
Study: 17943541

Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17beta-estradiol daily plus 10 mg dydrogesterone for 14 days of each 28-day cycle (n = 44)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (n = 36)
Number of subjects: 80
Study: 16230985

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (150 mg daily)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg) plus vitamin E (1,000 IU daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo run-in
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo wash-out
Number of subjects: 6
Study: 11717654

Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined hormone replacement therapy (0.3 mg conjugated equine estrogens and 2.5 mg medroxyprogesterone acetate plus 1000 mg calcium per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (1000 mg calcium per day alone)
Number of subjects: 60
Study: 9138278

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2a 3 MU three times weekly for 22 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2a 6 MU three times weekly for 22 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IFN therapy (both dosages)
Number of subjects: 88
Study: 7950032

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Management Protocol (CAMP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 58
Study: 3066430

Group type: EXPERIMENTAL
Intervention: Habit reversal training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 20
Study: 2195426

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 966243

Group type: EXPERIMENTAL
Intervention: Copper T 200 (T Cu 200)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dalkon shield
Number of subjects: 0
Study: 30357360

Group type: EXPERIMENTAL
Intervention: Twice-weekly haemodialysis (2×HD)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Thrice-weekly haemodialysis (3×HD)
Number of subjects: 565
Study: 28296003

Group type: EXPERIMENTAL
Intervention: Celt ACD®
Number of subjects: 207

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 207
Study: 26006264

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation Therapy (CRT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active Computerized Control (CC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 130
Study: 23370155

Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Medical circumcision
Number of subjects: 801

Group type: COMPARATOR
Intervention: Vaccine recipients
Number of subjects: 801
Study: 21997650

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 40
Study: 19858156

Group type: EXPERIMENTAL
Intervention: Standard parenteral nutrition solution
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aluminum exposure above the median (55 microg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aluminum-depleted parenteral nutrition solutions
Number of subjects: 59
Study: 17074322

Group type: EXPERIMENTAL
Intervention: Modified ovarian age-based stimulation with microdose GnRH agonist (GnRH-a) and 450-600 IU of gonadotropin daily.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard chronological age-based stimulation with long luteal phase GnRH-a and up to 300 IU of gonadotropins.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups achieved a 47% rate of first positive pregnancy test (hCG).
Number of subjects: 62
Study: 16010101

Group type: EXPERIMENTAL
Intervention: CO2 laser myringotomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adenoidectomy and ventilation tube (VT) insertion
Number of subjects: 25
Study: 11717641

Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 113

Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 113
Study: 9233079

Group type: EXPERIMENTAL
Intervention: Training workshop for selected members to spread knowledge and skills of oral rehydration therapy.
Number of subjects: 0
Study: 8123269

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 0.1 mEq/ml of sodium bicarbonate (NaHCO3)
Number of subjects: 184

Group type: COMPARATOR
Intervention: 1% lidocaine alone
Number of subjects: 184
Study: 2888018

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 29851791

Group type: EXPERIMENTAL
Intervention: Anti-TB therapy with isoniazid, rifampicin, ethambutol, and pyrazinamide for 6 months
Number of subjects: 1
Study: 27678430

Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 26618177

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (McL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pentax‐AWS Airwayscope (AWS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: McGRATH MAC (McGRATH)
Number of subjects: 17
Study: 23437399

Group type: EXPERIMENTAL
Intervention: Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s)
Number of subjects: 3316

Group type: COMPARATOR
Intervention: Clinically-Driven Monitoring (CDM, CD4s measured but blinded)
Number of subjects: 3316
Study: 20884430

Group type: EXPERIMENTAL
Intervention: XIENCE V(r) everolimus‐eluting stent (EES)
Number of subjects: 154

Group type: COMPARATOR
Intervention: TAXUS Express2(tm) paclitaxel-eluting stent (PES)
Number of subjects: 154
Study: 18226762

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17009166

Group type: EXPERIMENTAL
Intervention: Fortified whole milk
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unfortified whole milk
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fortified skimmed milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All types of milk (fortified whole, unfortified whole, and fortified skimmed)
Number of subjects: 19
Study: 12728487

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.3 ml (15 micrograms) added to 0.5% hyperbaric bupivacaine 2.0 ml
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% saline 0.3 ml added to 0.5% hyperbaric bupivacaine 2.0 ml
Number of subjects: 24
Study: 11483142

Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) plus work therapy (WT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Work therapy (WT) alone
Number of subjects: 65
Study: 9404379

Group type: COMPARATOR
Intervention: 0.9% NaCl + voluntary cough (Control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.0% NaCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.0% NaCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 12% NaCl
Number of subjects: 10
Study: 8314291

Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime i.v. at induction of anaesthesia (prophylaxis group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No antibiotics perioperatively (control group)
Number of subjects: 200
Study: 3111238

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 29
Study: 31501920

Group type: EXPERIMENTAL
Intervention: Greater height (HR per 10 cm)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Leg length
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Adjustment for liver fat and triacylglycerols, adiponectin and C-reactive protein
Number of subjects: 2500
Study: 28832288

Group type: EXPERIMENTAL
Intervention: Laboratory screening prior to ART
Number of subjects: 771
Study: 26056838

Group type: EXPERIMENTAL
Intervention: PVB with catheter at level Th 4, 10 ml each of 1:2 mixture of bupivacaine 0.5% and lidocaine 2% with adrenaline injected at three different levels
Number of subjects: 70

Group type: COMPARATOR
Intervention: General Anaesthesia (GA) with sevoflurane
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PVB with catheter
Number of subjects: 70

Group type: COMPARATOR
Intervention: GA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PVB with catheter and GA
Number of subjects: 70
Study: 23165913

Group type: EXPERIMENTAL
Intervention: Lactitol treatment
Number of subjects: 94
Study: 21639927

Group type: EXPERIMENTAL
Intervention: Standard care plus cooling (target rectal temperature of 33-34°C for 72 hrs, started within 3 h of birth)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Standard care plus cooling
Number of subjects: 36
Study: 19901110

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (arm A)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Procarbazine, lomustine (CCNU), and vincristine (PCV; arm B1)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Temozolomide (arm B2)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Hypermethylation of the MGMT promoter
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Mutations of the isocitrate dehydrogenase (IDH1) gene
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Oligodendroglial histology
Number of subjects: 318
Study: 16546486

Group type: EXPERIMENTAL
Intervention: PSE margarine (3 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo margarine (0 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aerobic exercise (400 kcal, 5 d/wk at 65% of VO2 reserve)
Number of subjects: 26
Study: 12775317

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using topical methyl aminolevulinate (Metvix)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 204
Study: 11236176

Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 120
Study: 8968971

Group type: EXPERIMENTAL
Intervention: Surgery (n = 22)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Physiotherapy (n = 24)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cervical collars (n = 25)
Number of subjects: 71
Study: 1533329

Group type: EXPERIMENTAL
Intervention: Lumbar iEMG during isotonic exercise (60% of maximum isometric torque)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eccentric exertion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concentric exertion
Number of subjects: 28

Group type: COMPARATOR
Intervention: iEMG fatigue slopes
Number of subjects: 28
Study: 6152058

Group type: EXPERIMENTAL
Intervention: RS 86, 0.5-4 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RS 86, 4 mg orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30073931

Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg/day for one week after each doxorubicin dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Silymarin and Placebo)
Number of subjects: 80
Study: 30089301

Group type: EXPERIMENTAL
Intervention: Vancomycin (7 days, 1,500 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amoxicillin (7 days, 1,500 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vancomycin and Amoxicillin
Number of subjects: 40
Study: 27456342

Group type: EXPERIMENTAL
Intervention: 1-week free nicotine replacement therapy (NRT) sample and medication counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice to purchase NRT on their own
Number of subjects: 0
Study: 24313236

Group type: EXPERIMENTAL
Intervention: Intake cotinine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Years smoked (self-report metric)
Number of subjects: 103
Study: 23477217

Group type: EXPERIMENTAL
Intervention: Systemic enzyme therapy in combination with antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 0
Study: 20591872

Group type: EXPERIMENTAL
Intervention: Vitrified oocytes
Number of subjects: 600

Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 600
Study: 17384344

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat-rich diet (MUFA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (CHO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saturated fat diet (SAT)
Number of subjects: 11
Study: 16304298

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 40
Study: 12230061

Group type: EXPERIMENTAL
Intervention: Intraabdominal passive gas drain left for four hours postoperatively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (no gas drain)
Number of subjects: 80
Study: 10470844

Group type: EXPERIMENTAL
Intervention: Standard regimen with CCNU, cyclophosphamide, adriamycin (CCA) and VP16
Number of subjects: 394

Group type: COMPARATOR
Intervention: Alternating regimen (CCA regimen alternating with cisplatin‐vindesine‐VP16)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Limited SCLC patients (Standard regimen)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Limited SCLC patients (Alternating regimen)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Alternating regimen
Number of subjects: 394
Study: 9360863

Group type: EXPERIMENTAL
Intervention: Random presentation order of stimulus level
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential presentation order of stimulus level
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-level referent presented at the start of each trial
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ascending runs in sequential presentation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Descending runs in sequential presentation
Number of subjects: 40
Study: 2030596

Group type: EXPERIMENTAL
Intervention: modified Anna Pavala Sindhooram (APSm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: withdrawal of APSm
Number of subjects: 30
Study: 7125153

Group type: EXPERIMENTAL
Intervention: Budesonide (topical steroid), 1-week pretreatment before nasal histamine challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, 1-week pretreatment before nasal histamine challenge
Number of subjects: 0
Study: 30467056

Group type: EXPERIMENTAL
Intervention: Loratadine+mometasone furoate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Loratadine+mometasone furoate+montelukast
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Montelukast+mometasone furoate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Montelukast+mometasone furoate+loratadine
Number of subjects: 108
Study: 31542275

Group type: EXPERIMENTAL
Intervention: Balloon guide catheter (BGC)
Number of subjects: 887

Group type: COMPARATOR
Intervention: No balloon guide catheter (BGC)
Number of subjects: 887
Study: 29074595

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 110

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 110
Study: 26365936

Group type: EXPERIMENTAL
Intervention: Phenotyping group (VerifyNow P2Y12 assay)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotyping group (CYP2C19 *2 allele testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard-dose clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24060143

Group type: EXPERIMENTAL
Intervention: Povidone iodine (PI) group (Gr I)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-povidone iodine (non-PI) group (Gr II)
Number of subjects: 55
Study: 22690673

Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW) for propofol clearance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Central volume of distribution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peripheral volume
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intercompartmental clearance
Number of subjects: 20
Study: 20199009

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% applied 30 minutes before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no brimonidine tartrate)
Number of subjects: 100
Study: 17571945

Group type: EXPERIMENTAL
Intervention: 30 mg/day lycopene (Lyc-O-Mato) plus a multivitamin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Multivitamin only
Number of subjects: 81
Study: 16263177

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sertraline plus IPT
Number of subjects: 94

Group type: COMPARATOR
Intervention: IPT
Number of subjects: 94

Group type: COMPARATOR
Intervention: BSP
Number of subjects: 94
Study: 12297174

Group type: EXPERIMENTAL
Intervention: Standard sternal wires (Group I)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Thermoreactive Nitillium clips (Group II)
Number of subjects: 1000